Development of treatment-decision algorithms for children evaluated for pulmonary tuberculosis: an individual participant data meta-analysis.
Journal
The Lancet. Child & adolescent health
ISSN: 2352-4650
Titre abrégé: Lancet Child Adolesc Health
Pays: England
ID NLM: 101712925
Informations de publication
Date de publication:
05 2023
05 2023
Historique:
received:
10
11
2022
revised:
06
01
2023
accepted:
10
01
2023
medline:
21
4
2023
pubmed:
17
3
2023
entrez:
16
3
2023
Statut:
ppublish
Résumé
Many children with pulmonary tuberculosis remain undiagnosed and untreated with related high morbidity and mortality. Recent advances in childhood tuberculosis algorithm development have incorporated prediction modelling, but studies so far have been small and localised, with limited generalisability. We aimed to evaluate the performance of currently used diagnostic algorithms and to use prediction modelling to develop evidence-based algorithms to assist in tuberculosis treatment decision making for children presenting to primary health-care centres. For this meta-analysis, we identified individual participant data from a WHO public call for data on the management of tuberculosis in children and adolescents and referral from childhood tuberculosis experts. We included studies that prospectively recruited consecutive participants younger than 10 years attending health-care centres in countries with a high tuberculosis incidence for clinical evaluation of pulmonary tuberculosis. We collated individual participant data including clinical, bacteriological, and radiological information and a standardised reference classification of pulmonary tuberculosis. Using this dataset, we first retrospectively evaluated the performance of several existing treatment-decision algorithms. We then used the data to develop two multivariable prediction models that included features used in clinical evaluation of pulmonary tuberculosis-one with chest x-ray features and one without-and we investigated each model's generalisability using internal-external cross-validation. The parameter coefficient estimates of the two models were scaled into two scoring systems to classify tuberculosis with a prespecified sensitivity target. The two scoring systems were used to develop two pragmatic, treatment-decision algorithms for use in primary health-care settings. Of 4718 children from 13 studies from 12 countries, 1811 (38·4%) were classified as having pulmonary tuberculosis: 541 (29·9%) bacteriologically confirmed and 1270 (70·1%) unconfirmed. Existing treatment-decision algorithms had highly variable diagnostic performance. The scoring system derived from the prediction model that included clinical features and features from chest x-ray had a combined sensitivity of 0·86 [95% CI 0·68-0·94] and specificity of 0·37 [0·15-0·66] against a composite reference standard. The scoring system derived from the model that included only clinical features had a combined sensitivity of 0·84 [95% CI 0·66-0·93] and specificity of 0·30 [0·13-0·56] against a composite reference standard. The scoring system from each model was placed after triage steps, including assessment of illness acuity and risk of poor tuberculosis-related outcomes, to develop treatment-decision algorithms. We adopted an evidence-based approach to develop pragmatic algorithms to guide tuberculosis treatment decisions in children, irrespective of the resources locally available. This approach will empower health workers in primary health-care settings with high tuberculosis incidence and limited resources to initiate tuberculosis treatment in children to improve access to care and reduce tuberculosis-related mortality. These algorithms have been included in the operational handbook accompanying the latest WHO guidelines on the management of tuberculosis in children and adolescents. Future prospective evaluation of algorithms, including those developed in this work, is necessary to investigate clinical performance. WHO, US National Institutes of Health.
Sections du résumé
BACKGROUND
Many children with pulmonary tuberculosis remain undiagnosed and untreated with related high morbidity and mortality. Recent advances in childhood tuberculosis algorithm development have incorporated prediction modelling, but studies so far have been small and localised, with limited generalisability. We aimed to evaluate the performance of currently used diagnostic algorithms and to use prediction modelling to develop evidence-based algorithms to assist in tuberculosis treatment decision making for children presenting to primary health-care centres.
METHODS
For this meta-analysis, we identified individual participant data from a WHO public call for data on the management of tuberculosis in children and adolescents and referral from childhood tuberculosis experts. We included studies that prospectively recruited consecutive participants younger than 10 years attending health-care centres in countries with a high tuberculosis incidence for clinical evaluation of pulmonary tuberculosis. We collated individual participant data including clinical, bacteriological, and radiological information and a standardised reference classification of pulmonary tuberculosis. Using this dataset, we first retrospectively evaluated the performance of several existing treatment-decision algorithms. We then used the data to develop two multivariable prediction models that included features used in clinical evaluation of pulmonary tuberculosis-one with chest x-ray features and one without-and we investigated each model's generalisability using internal-external cross-validation. The parameter coefficient estimates of the two models were scaled into two scoring systems to classify tuberculosis with a prespecified sensitivity target. The two scoring systems were used to develop two pragmatic, treatment-decision algorithms for use in primary health-care settings.
FINDINGS
Of 4718 children from 13 studies from 12 countries, 1811 (38·4%) were classified as having pulmonary tuberculosis: 541 (29·9%) bacteriologically confirmed and 1270 (70·1%) unconfirmed. Existing treatment-decision algorithms had highly variable diagnostic performance. The scoring system derived from the prediction model that included clinical features and features from chest x-ray had a combined sensitivity of 0·86 [95% CI 0·68-0·94] and specificity of 0·37 [0·15-0·66] against a composite reference standard. The scoring system derived from the model that included only clinical features had a combined sensitivity of 0·84 [95% CI 0·66-0·93] and specificity of 0·30 [0·13-0·56] against a composite reference standard. The scoring system from each model was placed after triage steps, including assessment of illness acuity and risk of poor tuberculosis-related outcomes, to develop treatment-decision algorithms.
INTERPRETATION
We adopted an evidence-based approach to develop pragmatic algorithms to guide tuberculosis treatment decisions in children, irrespective of the resources locally available. This approach will empower health workers in primary health-care settings with high tuberculosis incidence and limited resources to initiate tuberculosis treatment in children to improve access to care and reduce tuberculosis-related mortality. These algorithms have been included in the operational handbook accompanying the latest WHO guidelines on the management of tuberculosis in children and adolescents. Future prospective evaluation of algorithms, including those developed in this work, is necessary to investigate clinical performance.
FUNDING
WHO, US National Institutes of Health.
Identifiants
pubmed: 36924781
pii: S2352-4642(23)00004-4
doi: 10.1016/S2352-4642(23)00004-4
pmc: PMC10127218
pii:
doi:
Types de publication
Meta-Analysis
Journal Article
Research Support, U.S. Gov't, P.H.S.
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
336-346Subventions
Organisme : NIGMS NIH HHS
ID : T32 GM007205
Pays : United States
Organisme : NICHD NIH HHS
ID : K23 HD072802
Pays : United States
Organisme : NICHD NIH HHS
ID : R01 HD058971
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI137093
Pays : United States
Organisme : Medical Research Council
ID : MR/R007942/1
Pays : United Kingdom
Organisme : NIAID NIH HHS
ID : R01 AI147854
Pays : United States
Organisme : NICHD NIH HHS
ID : F30 HD105440
Pays : United States
Organisme : NIAID NIH HHS
ID : K23 AI143479
Pays : United States
Organisme : PEPFAR
Pays : United States
Organisme : FIC NIH HHS
ID : K43 TW011028
Pays : United States
Organisme : World Health Organization
ID : 001
Pays : International
Informations de copyright
© 2023 World Health Organization. Published by Elsevier Ltd. All rights reserved. This is an Open Access article published under the CC BY 3.0 IGO license which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. In any use of this article, there should be no suggestion that WHO endorses any specific organisation, products or services. The use of the WHO logo is not permitted. This notice should be preserved along with the article's original URL.
Déclaration de conflit d'intérêts
Declaration of interests We declare no competing interests.
Références
J Pediatric Infect Dis Soc. 2022 Mar 24;11(3):108-114
pubmed: 34902033
N Engl J Med. 2022 Mar 10;386(10):911-922
pubmed: 35263517
BMC Public Health. 2019 Apr 29;19(1):446
pubmed: 31035984
Stat Methods Med Res. 2019 Sep;28(9):2768-2786
pubmed: 30032705
Pediatrics. 2019 Sep;144(3):
pubmed: 31455612
Confl Health. 2020 May 14;14:26
pubmed: 32467723
Lancet Glob Health. 2017 Sep;5(9):e898-e906
pubmed: 28807188
Lancet Child Adolesc Health. 2022 Feb;6(2):106-115
pubmed: 34800370
J Clin Epidemiol. 2005 Oct;58(10):982-90
pubmed: 16168343
Clin Infect Dis. 2015 Oct 15;61Suppl 3:S179-87
pubmed: 26409281
Lancet Respir Med. 2015 Jun;3(6):451-61
pubmed: 25812968
Pathogens. 2021 Dec 01;10(12):
pubmed: 34959523
Int J Tuberc Lung Dis. 1998 Feb;2(2):116-23
pubmed: 9562121
Open Forum Infect Dis. 2021 Feb 18;8(3):ofab075
pubmed: 33738322
Trop Med Int Health. 2009 Nov;14(11):1329-37
pubmed: 19735381
BMJ. 2015 Jan 07;350:g7594
pubmed: 25569120
J Infect Dis. 2017 Nov 6;216(suppl_7):S702-S713
pubmed: 29117342
Int J Tuberc Lung Dis. 2018 Nov 1;22(11):1314-1321
pubmed: 30355411
Clin Infect Dis. 2021 Aug 16;73(4):e904-e912
pubmed: 33449999